Pharmacy benefit companies are strong proponents of a highly functioning biosimilar market. Bringing more biosimilars to market, over time, will allow PBMs to more effectively leverage competition to reduce drug costs for health plan sponsors and patients. As biosimilar competition
PBM Tools PBM Tools Will Save Health Plan Sponsors and Consumers More than $1 Trillion on Prescription Drug Costs As prescription drug spending continues to increase, research shows PBMs’ cost savings and patient care management tools should reduce prescription drug
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) applauds the Energy and Commerce Subcommittee on Oversight and Investigations for holding today’s hearing on the important issue of rising insulin prices. “Drugmakers are solely responsible for setting and raising prescription
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on today’s vote in the Energy and Commerce Subcommittee on Health on the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act:
(Washington, D.C.) — As Congress begins to examine high prescription drug prices, the Pharmaceutical Care Management Association (PCMA) sent letters to several congressional committees highlighting the value pharmacy benefit managers (PBMs) provide to patients and payers as well as outlining
Last week, the U.S. House Ways and Means Committee Health Subcommittee held a hearing on “Why Health Care is Unaffordable: Anticompetitive and Consolidated Markets.” During the hearing, Congressman Kevin Hern (R-OK) shared that, as a former business owner, he was
For millions of Americans, the prescription drug delivery system works: people, for the most part, can access the medications they need when they need them, and at the cost they expect and can afford. But “millions of Americans” does not
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) supports the Centers for Medicare and Medicaid Services’ (CMS) proposal to promote the use of biosimilars in Medicare Part D. Pharmacy benefit companies, or PBMs, have long supported the development of
©2024 PCMA. All Rights Reserved.
